|
1
|
Plasma levels of thromboxane A2 on admission are associated with no-reflow after primary percutaneous coronary intervention.
|
Eur Heart J
|
2008
|
1.66
|
|
2
|
VEGF-A gene promoter polymorphisms and microvascular complications in patients with essential hypertension.
|
Clin Biochem
|
2010
|
1.48
|
|
3
|
Inhibition of platelet aggregation by aspirin progressively decreases in long-term treated patients.
|
J Am Coll Cardiol
|
2004
|
1.15
|
|
4
|
Soluble P-selectin as a marker of in vivo platelet activation.
|
Clin Chim Acta
|
2008
|
1.06
|
|
5
|
Heavy chain myosin 9-related disease (MYH9 -RD): neutrophil inclusions of myosin-9 as a pathognomonic sign of the disorder.
|
Thromb Haemost
|
2010
|
0.98
|
|
6
|
Tumor necrosis factor-alpha as trigger of platelet activation in patients with heart failure.
|
Blood
|
2005
|
0.98
|
|
7
|
COX-1 sensitivity and thromboxane A2 production in type 1 and type 2 diabetic patients under chronic aspirin treatment.
|
Eur Heart J
|
2009
|
0.97
|
|
8
|
Prognostic significance of serum adipokine levels in colorectal cancer patients.
|
Anticancer Res
|
2009
|
0.96
|
|
9
|
Impact of chemotherapy on activated protein C-dependent thrombin generation--association with VTE occurrence.
|
Int J Cancer
|
2013
|
0.94
|
|
10
|
Biomarkers of platelet activation in acute coronary syndromes.
|
Thromb Haemost
|
2012
|
0.94
|
|
11
|
Enhanced TNF alpha and oxidative stress in patients with heart failure: effect of TNF alpha on platelet O2- production.
|
Thromb Haemost
|
2003
|
0.91
|
|
12
|
Platelet function in health and disease: from molecular mechanisms, redox considerations to novel therapeutic opportunities.
|
Antioxid Redox Signal
|
2012
|
0.88
|
|
13
|
Novel high-sensitive D-dimer determination predicts chemotherapy-associated venous thromboembolism in intermediate risk lung cancer patients.
|
Clin Lung Cancer
|
2012
|
0.85
|
|
14
|
Plasma plasminogen activator inhibitor-1 (PAI-1) levels in breast cancer - relationship with clinical outcome.
|
Anticancer Res
|
2014
|
0.84
|
|
15
|
Venous thromboembolism risk prediction in ambulatory cancer patients: clinical significance of neutrophil/lymphocyte ratio and platelet/lymphocyte ratio.
|
Int J Cancer
|
2014
|
0.84
|
|
16
|
Association between increased tumor necrosis factor alpha levels and acquired activated protein C resistance in patients with metastatic colorectal cancer.
|
Int J Colorectal Dis
|
2012
|
0.83
|
|
17
|
RFID as a new ICT tool to monitor specimen life cycle and quality control in a biobank.
|
Int J Biol Markers
|
2011
|
0.81
|
|
18
|
Predictive value of thrombopath determination in women with infertility and pregnancy complications.
|
Clin Chim Acta
|
2009
|
0.81
|
|
19
|
Impact of chemotherapy on venous thromboembolism: comment to: regional lymph node metastases are a strong risk factor for venous thromboembolism: results from the Vienna Cancer and Thrombosis Study.
|
Haematologica
|
2013
|
0.80
|
|
20
|
TNFA gene promoter polymorphisms and susceptibility to recurrent pregnancy loss in Italian women.
|
Reprod Sci
|
2010
|
0.80
|
|
21
|
HIT in VAD patients: considerations.
|
Ann Thorac Surg
|
2007
|
0.79
|
|
22
|
SPRECware: software tools for Standard PREanalytical Code (SPREC) labeling - effective exchange and search of stored biospecimens.
|
Int J Biol Markers
|
2012
|
0.79
|
|
23
|
Pleiotropic effects of PPARγ agonist on hemostatic activation in type 2 diabetes mellitus.
|
Curr Vasc Pharmacol
|
2013
|
0.79
|
|
24
|
Early changes of a novel APC-dependent thrombin generation assay during chemotherapy independently predict venous thromboembolism in cancer patients--a pilot study.
|
Support Care Cancer
|
2012
|
0.77
|
|
25
|
Impact of VEGF gene polymorphisms in elderly cancer patients: clinical outcome and toxicity.
|
Pharmacogenomics
|
2015
|
0.77
|
|
26
|
Lymphocytes as internal standard in oxidative burst analysis by cytometry: a new data analysis approach.
|
J Immunol Methods
|
2012
|
0.77
|
|
27
|
VEGF gene promoter polymorphisms and risk of VTE in chemotherapy-treated cancer patients.
|
Thromb Haemost
|
2015
|
0.77
|
|
28
|
Estimated glomerular filtration rate is an easy predictor of venous thromboembolism in cancer patients undergoing platinum-based chemotherapy.
|
Oncologist
|
2014
|
0.75
|
|
29
|
Predictive value of high-sensitive D-dimer determination for chemotherapy-associated venous thromboembolism in gastrointestinal cancer patients.
|
Thromb Haemost
|
2012
|
0.75
|
|
30
|
Anti-angiogenic drugs, vascular toxicity and thromboembolism in solid cancer.
|
Cardiovasc Hematol Agents Med Chem
|
2017
|
0.75
|